Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells 472 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Irene Becklund sold 472 shares of Hims & Hers Health stock in a transaction on Monday, December 16th. The shares were sold at an average price of $29.58, for a total value of $13,961.76. Following the completion of the transaction, the insider now owns 17,331 shares in the company, valued at $512,650.98. The trade was a 2.65 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Irene Becklund also recently made the following trade(s):

• On Monday, November 18th, Irene Becklund sold 472 shares of Hims & Hers Health stock. The shares were sold at an average price of $19.42, for a total value of $9,166.24.

Hims & Hers Health Price Performance

Hims & Hers Health stock opened at $26.36 on Friday. Hims & Hers Health, Inc. has a 1 year low of $8.09 and a 1 year high of $35.02. The firm has a 50-day moving average of $25.63 and a two-hundred day moving average of $21.23. The stock has a market cap of $5.76 billion, a price-to-earnings ratio of 59.91 and a beta of 1.25.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. During the same period in the previous year, the business posted ($0.04) EPS. The business’s quarterly revenue was up 77.1% compared to the same quarter last year. Research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Institutional Trading of Hims & Hers Health

Several hedge funds have recently made changes to their positions in HIMS. Nisa Investment Advisors LLC increased its stake in Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after purchasing an additional 1,603 shares during the period. Quest Partners LLC lifted its holdings in shares of Hims & Hers Health by 5,944.1% during the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after acquiring an additional 3,507 shares during the period. CWM LLC grew its stake in shares of Hims & Hers Health by 21.4% during the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after buying an additional 1,054 shares during the period. Van ECK Associates Corp acquired a new position in shares of Hims & Hers Health in the 2nd quarter valued at about $111,000. Finally, Quarry LP raised its stake in shares of Hims & Hers Health by 91.0% in the 3rd quarter. Quarry LP now owns 6,113 shares of the company’s stock valued at $113,000 after acquiring an additional 2,913 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on HIMS shares. Canaccord Genuity Group upped their price objective on shares of Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a report on Monday, December 2nd. Needham & Company LLC began coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They set a “buy” rating and a $24.00 price target for the company. Bank of America cut Hims & Hers Health from a “buy” rating to an “underperform” rating and reduced their price objective for the company from $32.00 to $18.00 in a research report on Thursday, November 14th. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $21.00 target price (up previously from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $22.80.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.